QBiotics is an Australian life sciences company, inspired by nature to improve human and animal health.
Our research and development program is based on compounds derived from the Australian tropical rainforest. Our product focus address unmet medical needs for humans and companion animals. We are currently concentrating on the global health priority areas of cancer, specifically solid tumours, and chronic wound management.
Our oncology product, EBC-46 (tigilanol tiglate), is a new approach to the treatment of solid tumour cancers. Results from human and veterinary clinical trials are supporting the drugs significant potential as an anticancer treatment. Development of tigilanol tiglate is making sound progress and plans are already underway for marketing the veterinary drug in the USA and Europe. Our wound healing product, EBC-1013 (WH-1), is addressing the problem of chronic wounds in a totally new way. Preclinical and early veterinary clinical development with WH-1 is proving to be most promising.
Our research and development program is based on compounds derived from the Australian tropical rainforest. Our product focus address unmet medical needs for humans and companion animals. We are currently concentrating on the global health priority areas of cancer, specifically solid tumours, and chronic wound management.
Our oncology product, EBC-46 (tigilanol tiglate), is a new approach to the treatment of solid tumour cancers. Results from human and veterinary clinical trials are supporting the drugs significant potential as an anticancer treatment. Development of tigilanol tiglate is making sound progress and plans are already underway for marketing the veterinary drug in the USA and Europe. Our wound healing product, EBC-1013 (WH-1), is addressing the problem of chronic wounds in a totally new way. Preclinical and early veterinary clinical development with WH-1 is proving to be most promising.
Location: Australia, Queensland, Brisbane City
Employees: 11-50
Founded date: 2004
Investors 1
| Date | Name | Website |
| - | TDM Asset ... | tdmgrowthp... |
Mentions in press and media 9
| Date | Title | Description |
| 25.06.2025 | QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA | BRISBANE, Australia, June 25, 2025 /PRNewswire/ -- Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced Soft Tissue Sarcoma... |
| 05.08.2024 | QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph... |
| 05.08.2024 | QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph... |
| 31.05.2023 | QBIOTICS TO PRESENT AT SACHS 9TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM AND THE BIO INTERNATIONAL CONVENTION | BRISBANE, Australia, May 31, 2023 /PRNewswire/ -- QBiotics Group Limited (QBiotics), a clinical stage life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals is pleased to announce that Richard God... |
| 25.07.2022 | US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL | Investigational new drug (IND) approval received by QBiotics, to initiate a Phase II clinical trial investigating tigilanol tiglate in the treatment of patients with Soft Tissue Sarcoma (STS) The open label trial will evaluate efficacy and ... |
| 16.12.2021 | AUSTRALIAN LIFE SCIENCE COMPANY, QBIOTICS, LAUNCHES STELFONTA® ITS LEAD VETERINARY PHARMACEUTICAL IN AUSTRALIA, FOLLOWING LAUNCHES IN OTHER KEY GLOBAL MARKETS | QBiotics commences the Australian commercial launch of its lead veterinary drug, STELFONTA®, which is approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumo... |
| 07.07.2021 | New Cancer Treatment For Australian Dogs With APVMA Approval Of Qbiotics' Stelfonta® | STELFONTA® (tigilanol tiglate) is now approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumours (MCT). APVMA approval follows marketing authorisation (regis... |
| 28.06.2021 | Qbiotics concludes successful $85 million capital raise | Capital raise nets $85 million from Existing Shareholders, Existing Institutional Investors, and cornerstone investor TDM Growth Partners. Funding to enable human clinical development of the Company's anticancer drug candidate tigilanol tig... |
| 03.06.2021 | First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma | First patient dosed with QBiotics' lead oncology molecule tigilanol tiglate in combination with KEYTRUDA® (pembrolizumab) in a clinical trial collaboration with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) The Phase Ib/IIa ... |